Written by: Marie C. Rush, PharmD, CPP, BCOP, Wake Forest Baptist Health Download Here  Description: The purpose of this PQI is to identify appropriate dosing of rasburicase based upon uric acid levels. Background: Rasburicase is an FDA approved intravenous medication for the management of serum uric acid levels in the setting of anticancer therapy that is expected to result in tumor lysis.1,2 While rasburicase breaks down uric acid […]

FOR IMMEDIATE RELEASE Cazenovia, NY – On November 12th, after feedback from healthcare professionals, UnitedHealthcare (UHC) announced that the implementation of their Accumulator Adjustment – Medical Benefit Program for their commercial members will NOT take effect on Jan. 1, 2021. This program would have prevented manufacturer assistance and co-pay programs from being accounted towards patient […]

Join AbbVie for their upcoming National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL, taking place on Thursday, 11/12 and Tuesday, 11/17 across multiple time zones. These educational events are in support of oncologists and care teams.  You may tailor the program to your audience by selecting to have the […]

MISSION STATEMENT/PHILOPSOPHY: To provide the most powerful team of cancer experts investing in the health of our patients by pursuing the most advanced and innovative treatment methods and providing unrelenting dedication to our patients.  LOCATIONS: Tulsa Oklahoma Bartlesville Oklahoma McAlester Oklahoma PRACTICE DETAILS (how many providers, how many employees, etc): 10 Medical Oncologists 4 Gyn […]

ONCOLYTICS TODAY Completes BPA Worldwide Initial Business Publication Audit SHELTON, CT, 10/5/20 – Oncolytics Today has completed its BPA Worldwide business publication audit. Glenn J. Hansen, BPA Worldwide President, praised Oncolytics Today for voluntarily opening its records to independent verification and documentation of its circulation data. Hansen pointed out that the audit facilitates the buying […]

MISSION STATEMENT/PHILOPSOPHY: To meet patients wherever they are on their cancer journey and walk with them on that journey; to provide compassionate, personalized cancer care for an unparalleled patient experience. LOCATIONS: Coeur D’ Alene, ID PRACTICE DETAILS (how many providers, how many employees, etc): 3 MO/DO 2 ARNP 20-25 employees INTRODUCTION TO PHARMACY SERVICES STAFF […]

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for […]

CAMBRIDGE, Mass., September 4, 2020 – Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung […]

MISSION STATEMENT/PHILOPSOPHY: Our vision is to provide an exceptional, unsurpassed health care experience at the Cone Health Cancer care program.  Our mission is to create a patient-centered, safe, high-quality, comprehensive program to meet the needs of our community. Through an empowered team, we will provide outstanding, collaborative, coordinated care with empathy and compassion that will […]

The industry-leading continuing pharmacy education provider becomes sole provider for association’s three major meetings through 2021 (CRANBURY, N.J. – August 23, 2020) – PTCE proudly announces it is now the exclusive continuing education (CE) provider for the National Community Oncology Dispensing Association, Inc. (NCODA) 2020-2021 meetings. See Full Press Release here

On June 18, 2020, the Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, […]

On June 22, 2020, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. Learn more Product Information Prescribing Information Relapsed or refractory […]